Victory Capital Management
ANIX icon

Victory Capital Management’s Anixa Biosciences ANIX Stock Holding History

Victory Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,606
Closed -$6K – 2537
2020
Q1 		$6K Buy
+3,606
New +$10.6K ﹤0.01% 3224
2019
Q4 		– Sell
-3,534
Closed -$14K – 2659
2019
Q3 		$14K Buy
+3,534
New +$14.8K ﹤0.01% 3148

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $8.43B AUM 52.02% 1-Year Est. Return

Victory Capital Management's ANIX Position: Q2 2020 in Review

Victory Capital Management sold out of Anixa Biosciences (ANIX) in Q2 2020, closing a stake of 3,606 shares — an estimated $6K sold.

Victory Capital Management first reported a position in ANIX in Q3 2019 and held it in 2 quarters. The position peaked at $14K in Q3 2019. 19 funds tracked by Wall St. Rank hold ANIX as of Q2 2020.

  • Victory Capital Management reported no remaining Anixa Biosciences position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 3,606 Anixa Biosciences shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Anixa Biosciences in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Anixa Biosciences position peaked at $14K in Q3 2019.
  • 19 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.